EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy

Yu-Te Huang, Peng-Tai Tien, Po-Yu Chen, Chi-Lan Yang, San-Ni Chen

Graefe's Archive for Clinical and Experimental Ophthalmology · 2024

DOI: 10.1007/s00417-024-06373-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2024. Verfasst von Yu-Te Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Eye Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, 40447, Taiwan. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Central Serous Chorioretinopathy, Visual Acuity. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To compare the efficacy of brolucizumab, half-dose PDT, and aflibercept in treating chronic central serous chorioretinopathy (CSC). METHODS: A retrospective cohort study with chronic CSC patients who underwent intravitreal injection of one shot of brolucizumab or aflibercept in the first 3 months, followed by pro re nata regimens or a single session of half-dose PDT, was retrospectively reviewed. The primary outcome measure was the proportion of eyes that achieved complete absorption of retinal fluid without requiring any rescue treatment. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and central choroidal thickness (CCT). RESULTS: A total of 54 consecutive patients were included in this study with 18 patients in each group. At months 1 and 2, the brolucizumab group exhibited the highest rate of complete retinal fluid resolution (61% and 77%), followed by the half-dose PDT group (56% and 72%), and lowest in the aflibercept group (28% and 33%), with statistically significant differences noted at month 2 (P = 0.012). The brolucizumab group also demonstrated the most significant reduction in CCT at months 1 and 2 among the three groups (P = 0.007 and 0.001). Recurrence of retinal fluid in the brolucizumab groups was predominantly observed at month 3. Conversely, the half-dose PDT group exhibited the most favorable anatomical results starting from month 3. Notably, mild vitritis was observed in one case from the brolucizumab group. CONCLUSIONS: Single injection of brolucizumab demonstrates trends of faster regression of persistent residual retinal fluid, greater CCT and CRT decline, and matched BCVA compared to half-dose PDT in the short term.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorCentral Serous ChorioretinopathyVisual AcuityIntravitreal InjectionsTomography, Optical CoherencePhotochemotherapyAngiogenesis InhibitorsFluorescein AngiographyHumansRetrospective StudiesMaleFemaleChronic DiseaseTreatment OutcomeMiddle AgedFollow-Up StudiesAdultPhotosensitizing AgentsAntibodies, Monoclonal, HumanizedFundus OculiDose-Response Relationship, DrugVascular Endothelial Growth Factor ARetina

Stichwörter der Autor:innen

AfliberceptBrolucizumabChronic central serous chorioretinopathyHalf-dose PDT

Substanzen

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAngiogenesis InhibitorsPhotosensitizing AgentsAntibodies, Monoclonal, HumanizedVascular Endothelial Growth Factor Aafliberceptbrolucizumab

Autor:innen und Institutionen

  • Department of Ophthalmology, Eye Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, 40447, Taiwan.
  • School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
  • Department of Ophthalmology, Eye Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, 40447, Taiwan. sanchen52@gmail.com.
  • School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. sanchen52@gmail.com.

Zitieren

APA

Huang, Y. T., Tien, P. T., Chen, P. Y., Yang, C. L., & Chen, S. N. (2024). Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06373-5

Vancouver

Huang YT, Tien PT, Chen PY, Yang CL, Chen SN. Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024. doi:10.1007/s00417-024-06373-5

BibTeX
@article{Huang2024,
  author = {Huang, Yu-Te and Tien, Peng-Tai and Chen, Po-Yu and Yang, Chi-Lan and Chen, San-Ni},
  title = {Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2024},
  doi = {10.1007/s00417-024-06373-5}
}
Kostenlos starten →